<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04258865</url>
  </required_header>
  <id_info>
    <org_study_id>A86_05BE1916P</org_study_id>
    <nct_id>NCT04258865</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Compare the Pharmacokinetics and Tolerability of CKD-348</brief_title>
  <acronym>CKD-348</acronym>
  <official_title>Phase I Clinical Trial to Compare the Pharmacokinetics and Tolerability of CKD-348 With Co-administration of CKD-828, D097 and D337 in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A clinical trial to compare the pharmacokinetics and tolerability of CKD-348
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, open-label, single-dose, 3-way crossover clinical trial to compare the
      pharmacokinetics and tolerability of CKD-348 with co-administrated drugs in healthy adult
      volunteers
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 25, 2020</start_date>
  <completion_date type="Actual">May 13, 2020</completion_date>
  <primary_completion_date type="Actual">April 26, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCt of CKD-348</measure>
    <time_frame>Pre-dose (0 hour)), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72 hours</time_frame>
    <description>AUCt: Area under the concentration-time curve from time zero to time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of CKD-348</measure>
    <time_frame>Pre-dose (0 hour)), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72 hours</time_frame>
    <description>Cmax: Maximum plasma concentration of the drug</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCinf of CKD-348</measure>
    <time_frame>Pre-dose (0 hour)), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72 hours</time_frame>
    <description>AUCinf: Area under the concentration-time curve from zero up to ∞</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of CKD-348</measure>
    <time_frame>Pre-dose (0 hour)), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72 hours</time_frame>
    <description>Tmax: Time to maximum plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of CKD-348</measure>
    <time_frame>Pre-dose (0 hour)), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72 hours</time_frame>
    <description>t1/2: Terminal elimination half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCt/AUCinf of CKD-348</measure>
    <time_frame>Pre-dose (0 hour), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72 hours</time_frame>
    <description>AUCt/AUCinf</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Hypertension</condition>
  <condition>Dyslipidemias</condition>
  <arm_group>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: CKD-828, D097, D337 - A single oral dose of 3 tablets under fasting conditions
Period 2: CKD-348 formulation 1 - A single oral dose of 1 tablet under fasting conditions
Period 3: CKD-348 formulation 2 - A single oral dose of 1 tablet under fasting conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: CKD-828, D097, D337 - A single oral dose of 3 tablets under fasting conditions
Period 2: CKD-348 formulation 2 - A single oral dose of 1 tablet under fasting conditions
Period 3: CKD-348 formulation 1 - A single oral dose of 1 tablet under fasting conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: CKD-348 formulation 1 - A single oral dose of 1 tablet under fasting conditions
Period 2: CKD-828, D097, D337 - A single oral dose of 3 tablets under fasting conditions
Period 3: CKD-348 formulation 2 - A single oral dose of 1 tablet under fasting conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: CKD-348 formulation 1 - A single oral dose of 1 tablet under fasting conditions Period 2: CKD-348 formulation 2 - A single oral dose of 1 tablet under fasting conditions Period 3: CKD-828, D097, D337 - A single oral dose of 3 tablets under fasting conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: CKD-348 formulation 2 - A single oral dose of 1 tablet under fasting conditions
Period 2: CKD-828, D097, D337 - A single oral dose of 3 tablets under fasting conditions
Period 3: CKD-348 formulation 1 - A single oral dose of 1 tablet under fasting conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: CKD-348 formulation 2 - A single oral dose of 1 tablet under fasting conditions
Period 2: CKD-348 formulation 1 - A single oral dose of 1 tablet under fasting conditions
Period 3: CKD-828, D097, D337 - A single oral dose of 3 tablets under fasting conditions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-348 F1</intervention_name>
    <description>QD, PO</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_label>Sequence 5</arm_group_label>
    <arm_group_label>Sequence 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-348 F2</intervention_name>
    <description>QD, PO</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_label>Sequence 5</arm_group_label>
    <arm_group_label>Sequence 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-828, D097, D337</intervention_name>
    <description>QD, PO</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_label>Sequence 5</arm_group_label>
    <arm_group_label>Sequence 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy adult volunteers aged ≥ 19-year-old

          2. Weight ≥ 50kg (man) or 45kg (woman), with calculated body mass index(BMI) of 18 to 30
             kg/m2

          3. Those who are eligible for adequate blood pressure criteria during screening tests
             Systolic blood pressure: 90 to 139 mmHg Diastolic blood pressure: 60 to 89 mmHg

          4. Those who have no congenital chronic disease or chronic disease requiring treatment
             and who have no pathological symptoms or findings

          5. Those who are eligible for clinical trials based on laboratory (hematology, blood
             chemistry, serum, urine test) and 12-lead ECG results during screening tests

          6. Those who agree to contraception during the participation of clinical trial

          7. Those who voluntarily decide to participate and agree to comply with the cautions
             after hearing and fully understanding the detailed description of this clinical trial

        Exclusion Criteria:

          1. Those who received investigational product or bioequivalence test drug within 6 months
             before the first administration of clinical trial drug

          2. Those who take barbiturate and related (causing induction or inhibition of metabolism)
             drug within 1 month before the first administration of clinical trial drug

          3. Those who donated whole blood and apheresis within 2 months or received transfusion
             within 1 month

          4. Those who has a history of gastrointestinal surgery (

          5. Those who exceeding an alcohol and smoke consumption criteria Alcohol: Men - 21
             glass/week, Women - 14 glass/week (1 glass: Soju 50 mL, Beer 250mL, Wine 30mL) Smoke:
             20 cigarettes/day

          6. Those who has a disease history of diabetic mellitus, nephropathy, biliary
             obstruction, shock, dihydropyridine sensitivity, angioedema, cardiac insufficiency

          7. Genetic problems such as galactose intolerance, Lapp lactose deficiency or
             glucose-galactose malabsorption

          8. Those who are deemed unfit by the investigators to participate in the clinical trial
             for other reasons including the results of laboratory tests

          9. Women who are pregnant or who may be pregnant and breastfeed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yook-Hwan Noh, M.D., PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>H Plus Yangji Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>H Plus Yangji Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Gwanak-gu</state>
        <zip>08779</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>February 5, 2020</study_first_submitted>
  <study_first_submitted_qc>February 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2020</study_first_posted>
  <last_update_submitted>June 3, 2020</last_update_submitted>
  <last_update_submitted_qc>June 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CKD-348</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

